SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AMLN (DIABETES DRUGS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2173 62 0 AMLN
Emcee:  eric siegel Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2123Amylin restructures: Message 25162350 Cheers, Tucktuck-11/10/2008
2122Bought some AMLN a couple of days ago. I think pancreatitis is likely a class ekenhott111/7/2008
2121Here is a bit more encouraging info on AMLN: "Fortunately AMLN has a "mlkr-11/5/2008
2120Down from $47 to $8. Doesnt make sense.. Another board member informed me that mlkr-11/5/2008
2119Recovering some!mlkr-11/5/2008
2118<i>(ALKS filing)......</i> Item 8.01 Other Events Alkermes, Inc. scaram(o)uche-11/4/2008
2117Was wondering the same. >> Blows me away that at $800M in annual sales, tscaram(o)uche-10/22/2008
2116Blows me away that at $800M in annual sales, they're still losing $250M annurkrw-10/22/2008
2115>> even before he picked up his British accent! << :-) I have faitscaram(o)uche-10/22/2008
2114Rick- I have not followed the company too closely of late, but am curious regarBiotech Jim-10/22/2008
2113Pancreatitis kills, necrotizing......... good to worry about it, and, if incscaram(o)uche-10/22/2008
2112Byetta, 2nd quarter, did 177.5 million. 179.9 million 3rd quarter... a push.scaram(o)uche-10/21/2008
2111Meanwhile, light on revenue, ~ 10 million under consensus. EPS is tougher: constuck-10/21/2008
2110Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly Tuesday Oscaram(o)uche-10/21/2008
2109>>Biotech Stock Mailbag: Rick H. from California asks "Don't you tuck-10/17/2008
2108Biotech Stock Mailbag: Rick H. from California asks "Don't you ever gescaram(o)uche-10/17/2008
21071. Pancreatitis is a common problem with a number of approved drugs. I only nescaram(o)uche-10/17/2008
2106Not really new data; they were reported in top-line form four months ago: silicDewDiligence_on_SI-10/17/2008
2105>>New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide Istuck-10/17/2008
2104<i>Metabolic Syndrome 2008</i>...... nature.comscaram(o)uche-10/15/2008
2103>> I mean why not, it's working SO well << The complete ban on scaram(o)uche-10/4/2008
2102>>Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blootuck-10/4/2008
2101clinicaltrials.gov Was thinking that some data from this trial might be availabscaram(o)uche-10/3/2008
2100Lehman and WaMu both ended life on reg sho. SEC doesn't have a clue who is scaram(o)uche-10/3/2008
2099Wasn't talking about data from Amylin, LAR or otherwise. Was thinking liragscaram(o)uche-10/3/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News